-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 20, 2022, the team of Professor Zhang Xiaohui, Institute of Hematology, Peking University People's Hospital, on low-dose rituximab (LD-RTX) combined with all-trans retinoic acid (ATRA) in the treatment of hormone-resistant or recurrent immune thrombocytopenia Symptomatic (ITP) research results, published in the international high-level journal Blood , and selected to provide Continuing medical education (CME)
All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP The study is a multi-center, open-label, randomized controlled, investigator-initiated clinical trial comparing ATRA combined with LD-RTX and LD-RTX monotherapy for hormone-resistant/relapsed ITP.
The results of the study showed that the 1-year overall response rate in the ATRA combined with LD-RTX group was significantly higher than that in the LD-RTX single-agent group (80% vs 59%, rate difference 0.
The first author of the research results is Wu Yejun, a 2016 eight-year clinical student , and the corresponding authors are Huang Xiaojun, director of the Institute of Hematology, Peking University People's Hospital, and Zhang Xiaohui, deputy director